Brought to you by 
CAT, Merck & Co. develop infectious disease therapeutics
22 Jul 2002
Executive Summary
In a five-year agreement, Cambridge Antibody Technology and Merck & Co. will jointly develop prophylactic and therapeutics for infectious diseases mediated by the HIV virus.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com